Astellas Pharma and 4D Molecular Therapeutics have entered into a license agreement that grants Astellas the rights to utilize 4DMT’s intravitreal retinotopic R100 vector for treating rare monogenic ophthalmic diseases.
The agreement allows Astellas to use the adeno-associated virus (AAV) vector for “one genetic target implicated in rare monogenic ophthalmic disease(s),” with the option to add up to two additional targets after paying additional option exercise fees, according to a press release. Astellas will deliver its own unique genetic payloads using R100, which is